Clinical trials: System Lupus Erythematosus
Systemic Lupus Erythematosus, Immunoglobulin A Nephropathy
The Genital Tract Microflora in Women With Systemic Lupus Erythematosus (SLE) and Immunoglobulin A (IgA) Nephropathy.
The study hypothesis: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a broad spectrum of clinical manifestations. Its mechanisms are not well understood.
- Trial name
- NCT05132621
- Testing
- Smear
- Where
- Poland
- Volunteers
- 150 people
- Sponsor
- Medical University of Warsaw
Systemic Lupus Erythematosus
A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of RO7507062 in participants with systemic lupus erythematosus (SLE).
- Trial name
- NCT05835986
- Testing
- RO7507062, Tocilizumab
- Where
- 18 sites in Colombia, France and 11 more
- Volunteers
- 70 people
- Sponsor
- Hoffmann-La Roche
Lupus Erythematosus, Systemic
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
This is a Phase II/III open label, single-arm, multicenter, extension study to evaluate the safety and efficacy of rituximab when administered on a scheduled basis every 6 months over the course of 1 year with reassessment of…
- Trial name
- VOYAGER (NCT00381810)
- Testing
- Rituximab, Methylprednisolone, Acetaminophen
- Where
- 11 sites in United States
- Volunteers
- 31 people
- Sponsor
- Genentech, Inc.
Systemic Lupus Erythematosus, SLE
Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus
This is a phase IIb, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of orelabrutinib in adult subjects with SLE who are receiving standard of care (SOC) therapy.
- Trial name
- NCT05688696
- Testing
- Orelabrutinib (Low Dose), Orelabrutinib (High Dose)
- Where
- 41 sites in China
- Volunteers
- 186 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Systemic Lupus Erythematosus, Rheumatoid Arthritis
A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
This study looks at a study medicine called MK-1045 in people with lupus and rheumatoid arthritis (RA). The main goal of the study is to learn about the safety of MK-1045 and if people tolerate it when they receive it at…
- Trial name
- NCT07363590
- Testing
- MK-1045
- Where
- 21 sites in Australia, Belgium and 9 more
- Volunteers
- 21 people
- Sponsor
- Merck Sharp & Dohme LLC
Systemic Lupus Erythematosus, Glucocorticoids
Glucocorticoids Withdrawal in Early Systemic Lupus Erythematosus
This is a 36 months, randomized, double-blind, placebo-controlled, parallel-groups, equivalence multicenter trial in patients with inactive Systemic Lupus Erythematosus to evaluate if low disease activity can be sustained with…
- Conditions
- Systemic Lupus Erythematosus, Glucocorticoids, Therapy Withdrawal
- Trial name
- NCT03804723
- Testing
- oral Prednisone 5mg
- Volunteers
- 321 people
- Sponsor
- University of Pisa
Lupus Nephritis (LN), Lupus Nephritis - WHO Class III
Safety and Efficacy of ONT01 in Lupus
ONT01 is a drug that is being studied for the treatment of Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) and is not approved by the FDA.
- Conditions
- Lupus Nephritis (LN), Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Lupus Nephritis - World Health Organization (WHO) Class III
- Trial name
- NCT07107659
- Testing
- ONT01 is a small molecule CD11b modulator.
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Hospital for Special Surgery, New York
SLE
A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
To evaluate the safety, tolerability, pharmacokinetics and pharmacokinetics of multi-dose APG-2575 in mild-to-moderate systemic lupus erythematosus (SLE).
- Trial name
- NCT06182969
- Testing
- APG-2575
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ascentage Pharma Group Inc.
Systemic Lupus Erythematosus (SLE)
A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus
This is a prospective, single-arm, open-label, dose-exploration and expansion clinical study of LCAR-AIO in adult subjects with relapsed/refractory systemic lupus erythematosus.
- Trial name
- NCT06653556
- Testing
- LCAR-AIO T cells
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Systemic Lupus Erythematosus, Cutaneous Lupus
Duke Lupus Registry
Lupus is a systemic autoimmune disease that can present with many varied symptoms, including joint pain, fevers, kidney disease, and rashes. Lupus can affect anyone, but it is most common in younger women.
- Trial name
- NCT00512694
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Duke University
Lupus Nephritis
Association Between Neuropathy and Some Autoantibodies in Systemic Lupus Erythematosus (SLE) Patients
1. Frequency of peripheral neuropathy associated with lupus nephritis 2. Sensitivity and specificity of some biomarkers used in diagnosis and follow up of SLE with lupus nephritis and peripheral neuropathy
- Trial name
- NCT06610422
- Volunteers
- 159 people
- Sponsor
- Assiut University
Systemic Lupus Erythematosus
Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care
This study will be conducted to assess the safety, tolerability, and immunogenicity of repeat doses of BOS161721 (20 milligrams [mg], 60 mg, and 120 mg) administered subcutaneously in adult participants with moderately to…
- Trial name
- NCT03371251
- Testing
- BOS161721
- Where
- 68 sites in United States, Argentina and 10 more
- Volunteers
- 143 people
- Sponsor
- Boston Pharmaceuticals
Systemic Lupus Erythematosus, SLE
JBT-101 in Systemic Lupus Erythematosus (SLE)
The objective of this study is to evaluate the efficacy, safety, and tolerability of JBT-101 (also known as lenabasum) in systemic lupus erythematosus (SLE).
- Conditions
- Systemic Lupus Erythematosus, SLE, Lupus
- Trial name
- NCT03093402
- Testing
- JBT-101
- Where
- 16 sites in United States
- Volunteers
- 109 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lupus Erythematosus, Rheumatoid Arthritis
Analysis of B Cells From Autoimmune Individuals
This observational study aims at finding out if individual with autoimmunity exhibit increased numbers of B cells that express two types (instead of one type) of antibodies, and if B cells of individuals genetically susceptible…
- Conditions
- Lupus Erythematosus, Rheumatoid Arthritis, Type 1 Diabetes
- Trial name
- NCT02747277
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Colorado, Denver
Lupus Nephritis
The Iguratimod Effect on Lupus Nephritis (IGeLU)
This study is a 52-week, randomized, open, active-controlled trial of patients with active diffused lupus nephritis, to assess the efficacy and safety of a novel chemical synthetic agent iguratimod.
- Trial name
- IGeLU (NCT02936375)
- Testing
- Iguratimod, Cyclophosphamide, Azathioprine
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- RenJi Hospital
Systemic Lupus Erythematosus
Umbilical Cord Derived Mesenchymal Stem Cells Transplantation for Active and Refractory Systemic Lupus Erythematosus
This study will explore safety and efficacy of allogeneic umbilical cord (UC) derived mesenchymal stem cells transplantation (MSCT) to treat patients with active and refractory systemic lupus erythematosus (SLE) who have been…
- Trial name
- NCT01741857
- Testing
- human umbilical cord derived MSC transplantation for SLE
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Lupus Erythematosus, Systemic
Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE.
The primary objective of the study is to evaluate the safety, tolerability, and efficacy of 4 weeks intravenous treatment with Cpn10 in subjects with mild to moderate active SLE.
- Trial name
- NCT01838694
- Testing
- Ala-Cpn10
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Invion, Inc.
Systemic Lupus Erythematosus, Lupus
Lupus Interval Monitoring to Manage Disease Flare and Enable Treatment Optimization
To develop a test to characterize and monitor SLE disease activity status from a participant's home by analyzing the gene expression from participant self-collected blood samples using a novel fingerstick collection kit.
- Conditions
- Systemic Lupus Erythematosus, Lupus, Lupus Erythematosus, Lupus Erythematosus, Systemic
- Trial name
- LIFT (NCT03142412)
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- DxTerity Diagnostics
Systemic Lupus Erythematosus
Study of AC0058TA in Patients With Systemic Lupus Erythematosus (SLE)
This is a Phase 1b, double blind, randomized, placebo-controlled study of the safety and tolerability, pharmacokinetics and pharmacodynamics of AC0058TA in patients with systemic lupus erythematosus (SLE).
- Trial name
- NCT03878303
- Testing
- AC0058TA
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- ACEA Therapeutics, Inc.
Transplantation, Systemic Lupus Erythematosus
Multicenter Trial Evaluating the Immunogenicity of HPV Vaccination in Girls on Immunosuppressive Therapy.
PRIMAVERA is a Phase IIa clinical trial, with the objective to assess the immunologic response to HPV vaccine in a population of immunocompromised girls.
- Conditions
- Transplantation, Systemic Lupus Erythematosus, Systemic Immune Disease
- Trial name
- PRIMAVERA (NCT01687192)
- Testing
- HPV prophylactic vaccine Gardasil
- Where
- 9 sites in France
- Volunteers
- 37 people
- Sponsor
- University Hospital, Bordeaux
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.